![[PRC HOME]](images/prclogo.jpg)
| Pharmacotherapy Research Center |
 |
 |
|
||
|
|
|||
|
AIDS Clinical Trials Group Pharmacology Specialty Laboratory
Bioanalytical Method Development, Validation, and Operations The Pharmacotherapy Research Center’s Core Analytical Laboratory ( PRC CAL) is one of four national pharmacology specialty laboratories (PSL) responsible for specialty laboratoryassignmentsfor pharmacologic assays for the AIDS Clinical Trials Group (ACTG). The ACTG is the largest HIV clinical trials organization in the world. The network plays a major role in setting standards of care for HIV infection and opportunistic diseases related to HIV/AIDS in the United States and the developed world. The ACTG is composed of, and directed by, leading clinical scientists in HIV/AIDS therapeutic research. Dr. Gene Morse, the director of the PRC CAL and the principal investigator for this laboratory award, participates in the development, implementation, management and analysis of outcomes for protocols conducted by the ACTG via participation in the ACTG’s committees and protocols teams. Other PRC CAL members, Dr. Robert DiCenzo, Ms Katherine (Kelly) Tooley and Ms. Robin DiFrancesco also participate in the ACTG committees and protocols as members. In addition the PRC CAL is the organizing laboratory for the Pharmacology Quality Assurance (PQA) program that oversees the quality of pharmacology activities for both the ACTG and International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) networks. The ACTG is funded by the Department of Health and Human Services, National Institutes of Health through the National Institute of Allergy and Infectious Diseases. Laboratory Publications of Methods: FrerichsVA, DiFrancesco R, Morse GD. Determination of Protease Inhibitors Using Liquid Chromatography Coupled To Tandem Mass Spectrometry, J. Chrom. B, 787, 2003, 393-403. Keil K, FrerichsVA, DiFrancesco R, Morse GD. Reverse Phase High Performance Liquid Chromatography Method For the Analysis of Amprenavir, Efavirenz, Indinavir, Lopinavir, Nelfinavir and Its Active Metabolite, M8, Ritonavir, and Saquinavir in Heparinized Human Plasma. Therapeutic Drug Monitoring, 25, 2003, 340-346. K Keil, R DiFrancesco, GD Morse. Determination of Tipranavir In Human Plasma by Reverse Phase Liquid Chromatography with UV Detection using Photodiode Array. Ther Drug Monitoring 2006 Aug 28(4);512-6 K Keil, J Hochreiter, R DiFrancesco, (others) GD Morse. Integration of Atazanavir into an Existing Liquid Chromatography UV Method of Protease Inhibitors: Validation and Application. Ther Drug Monit 2007.
PRC CAL Specialty laboratory assignments for pharmacologic assays CURRENT: A5202: EFV or ATV with RTV combined with FTC/TDF or ABC/3TC in Naive Subjects The following was taken from http://www.aactg.org/clinicaltrials_research.asp#study-A5202 “To learn whether the medication combinations work equally well in patients who have never taken HIV medications before. It will also look at how easy the medications are to take and their side effects…. Efavirenz (Sustiva), atazanavir (Reyataz), ritonavir (Norvir), FTC/tenofovir (Truvada combination pill), and abacavir/3TC (Epzicom combination pill) will be provided by the study…… Each patient will go into one of four groups taking a different set of HIV medications. Patients will know if they are taking efavirenz or atazanavir with ritonavir. They will not know whether they are taking abacavir/lamivudine or emtricitabine/tenofovir. Each medication will be taken once daily. Initial Treatment: Group A: efavirenz + FTC (emtricitabine)/tenofovir + abacavir/3TC (lamivudine) placebo Group B: efavirenz + abacavir/3TC + FTC/tenofovir placebo Group C: atazanavir with ritonavir + FTC/tenofovir + abacavir/3TC placebo Group D: atazanavir with ritonavir + abacavir/3TC + FTC/tenofovir placebo Duration of Study: About 2 years after the last person starts the study….. Participating Sites (find contact information) * University of Alabama at Birmingham * University of Miami * University of Texas, Galveston * Indiana University Hospital * Wishard Memorial * St. Mary's Hospital * San Mateo County AIDS Program * Willow Clinic * Stanford University Medical School * University of Pennsylvania * Presbyterian Medical Center * Boston Medical Center * The Ohio State University * University of Rochester Medical Center * Community Health Network, Inc. * Hawaii ACTU * Beth Israel Deaconess Medical Center * University of Pittsburgh * Washington University ( St. Louis) * Cook County Bureau of Health Services * Santa Clara Valley Medical Center * Duke University Medical Center * SUNY-Buffalo * Bellevue Hospital (NYU) * University of North Carolina * Moses H. Cone Hospital-IMPT * Wake County Human Services * Georgetown University Medical Center * MetroHealth Medical Center * University of Nebraska * University of Southern California * University of Iowa Hospitals and Clinic * University of California * Emory University * Case Western/University Hospitals of Cleveland * Harvard ( Massachusetts General Hospital) * Hennepin County Medical Center * University of Washington * University of Washington General Clinical Research * University of Washington Primary Infection Clinic * Brigham and Women's Hospital * Cornell Clinical Trials Unit * Cornell Clinical Trials Unit- Chelsea * Rush-Presbyterian/St.Lukes * Columbia Presbyterian Center of New York Presbyterian Hospital * UCLA Care Center * San Francisco General Hospital * University of California, San Diego * Comprehensive Care Center * Harbor/ UCLA * Johns Hopkins University * University of Minnesota * University of Cincinnati * University of Puerto Rico * The University of Texas Southwestern Medical Center at Dallas * The Miriam Hospital * Rhode Island Hospital * Stanley Street Treatment and Resource (SSTAR) * Beth Israel Medical Center * University of Colorado Health Science Center * Northwestern University” The UB PRCCAL assignment:
A5175: Once-Daily PI + Non-NRTI Regimens for Initial Treatment in Resource-Limited Settings The following was taken from http://www.aactg.org/clinicaltrials_research.asp#study-A5175 “This study will learn if two different once-daily combinations of anti-HIV drugs work as well as the standard twice-a-day combination of anti-HIV drugs for the initial treatment of individuals infected with HIV-1 who are from diverse areas of the world…. The study drugs are 3TC/ZDV, FTC, TDF, EFV, ATV, ddI-EC, NVP, ZDV, and d4T. Study drugs will be provided to participants while they are on study. However, only participants at international site will be provided 3TC/ZDV and ZDV……. Initial Treatment: Participating Sites * Lilongwe Central Hospital Campus, Lilongwe * University of Witwatersrand, Johannesburg * University of KwaZulu-Natal, Durban * Asociacion Civil IMPACTA Salud y Educacion, Mirafl * Asociacion Civil IMPACTA Salud y Education, Lince * Les Centres GHESKIO, Port-au-Prince Haiti * Chiang Mai University, Chiang Mai * National AIDS Research Institute, Pune * YRG Centre for AIDS Research and Education, Chennai * University of Zimbabwe, Harare * University of Malawi, Blantyre * Oswaldo Cruz Foundation, Rio de Janeiro * Hospital Nossa Senhora da Conceicao, Porto Alegre * University of Colorado Health Science Center * Cornell Clinical Trials Unit- Chelsea * Comprehensive Care Center * Harbor/ UCLA * Marin County Department of Health * University of North Carolina * Moses H. Cone Hospital-IMPT * The Miriam Hospital * Rhode Island Hospital * Stanley Street Treatment and Resource (SSTAR) * UCLA Care Center * Wake County Human Services * Columbia Presbyterian Center of New York Presbyterian Hospital * Washington University ( St. Louis) * Duke University Medical Center * University of Rochester Medical Center * Community Health Network, Inc. * University of Texas, Galveston * University of Pennsylvania * Presbyterian Medical Center * Hawaii ACTU * University of Alabama at Birmingham * University of California * The University of Texas Southwestern Medical Center at Dallas * The Ohio State University * Bellevue Hospital (NYU) * University of Minnesota * Rush-Presbyterian/St.Lukes * Beth Israel Medical Center * Cook County Bureau of Health Services * University of Cincinnati * Northwestern University * University of Maryland, Institute of Human Virology * San Mateo County AIDS Program * Willow Clinic * Stanford University Medical School * Santa Clara Valley Medical Center * University of Southern California * San Francisco General Hospital * University of Puerto Rico”
The UB PRCCAL assignment:
ACTG5146: A PHASE II RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF THERAPEUTIC DRUG MONITORING (TDM) ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN IN SUBJECTS WITH A NORMALIZED INHIBITORY QUOTIENT (NIQ) ≤ 1 TO ONE OR MORE PROTEASE INHIBITORS ACTG5146 will compare the effectiveness of using increased doses of protease inhibitor (PI) drugs to continuing standard doses of PIs in lowering viral load (amount of HIV in the blood) in patients who have failed previous drug regimens that included at least one protease inhibitor. The dose increases of the PI drugs will be based upon Therapeutic Drug Monitoring (TDM) and viral phenotype, which involves measuring blood levels of PIs and the virtual phenotype. All ACTG clinical sites were registered to participated in this study. The UB PRCCAL assignment:
ACTG384: Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor with Dual Nucleosides in Initial Therapy of HIV Infection This study was designed to look at which combinations of anti-HIV drugs are the safest and most effective way to treat HIV infection over a long period of time. It accrued over 900 patients. This study was done to learn how well different combinations of drugs can decrease the amount of HIV in the blood (viral load) to less than 200 copies of virus in a milliliter of blood (which is the lowest reliable level that can now be measured in the laboratory) and how well each combination maintains the low level of virus. In addition, the order in which the drugs are received when one regimen fails, was built into the study design allowing a patient to be given drug therapy and remain in the study. Lastly, it considers whether a 3 or 4 drug combination is best. This study used zidovudine, lamivudine, stavudine, didanosine, nelfinavir, and efavirenz, indinavir, amprenavir, and hydroxyurea in various combinations. The UB PRCCAL assignment:
PAST: ACTG 5043 – Pharmacokinetic Interaction Studies of Amprenavir, Efavirenz, and a Second Protease Inhibitor in Seronegative Volunteers Morse GD, Rosenkranz S, Para MF, Segal Y, DiFrancesco R, Adams E, Brizz B, Yarasheski KE, Reichman RC, and the 5043 Protocol Team. Amprenavir and Efavirenz Pharmacokinetics before and after the Addition of Nelfinavir, Indinavir, Ritonavir, or Saquinavir. Antimicrob Agents Chemother. 2005; 49(8):3373-81. Okusanya O, Forrest A, Difrancesco R, Balic S, Rosenkranz S, Para MF, Adams E, Yarasheski KE, Reichman RC, Morse GD. Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peaks. Antimicrob Agents Chemother. 2007 Feb 5. Rosenkranz SL, Yarasheski KE, Para MF, Reichman RC, Morse GD and the ACTG A5043 Team. Lipid and lipoprotein changes during short-term protease inhibitor and efavirenz exposure in HIV-seronegative subjects. Metabolic Syndrome 2007 (In press). Laboratory Analyses: By LCMSMS – Amprenavir, Efavirenz, Nelfinavir and its active metabolite, Saquinavir, Ritonavir, Indinavir PK Analyses ACTG 5076 - HIV-1 Resistance Testing During Antiretroviral Failure: Comparison of Sequencing Versus Phenotyping Laboratory Analyses: by HPLC – amprenavir, indinavir, nelfinavir and its active metabolite, ritonavir, saquinavir, efavirenz, nevirapine, abacavir ACTG 398 - A Phase II, Rand Trial of APV as Pt of Dual PI Regimens (Placebo Controlled) in Comb w/ ABC, EFV & ADV vs. APV Alone in HIV Infected Subjects w/Prior Expo. to Approved PIs and Loss of Virologic Supp. as Reflected By A Plasma HIV-1 RNA of >= 1000 copies/ml Laboratory Analyses: by HPLC efavirenz ACTG384: Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor with Dual Nucleosides in Initial Therapy of HIV Infection Shafer RW, Smeaton LM, Robbins GK, DeGrutolla V, Synder SW, D’Aquila RT, Johnson VA, Morse GD, Nokta MA, Martiznez A, Kaul P, Haubrich R, Swingle M, McCarty D, Vella S, Hirsch MS, Merigan TC. Strategies for Initial Antiretroviral Treatment of HIV-1 Infection: Comparison of Four-Drug Versus Sequential Three-Drug Regimens. N Engl J Med. 2003;349: 2304-15 Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD; ACTG 384-5006 Team. Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61. Laboratory Analyses: by HPLC efavirenz, nelfinavir and its active metabolite PK analyses ACTG 372A - A Phase II Study of the Prolongation of Virologic Success & Options for Vir. Failure in HIV-Infected Subj. Receiving IDV in Comb. with Nucleoside Analogs: A Rollover Study to ACTG 320 IAS 2005 Presentation: The Renal Safety of Long-Term Indinavir (IDV) Therapy in Subjects in ACTG 372A. Gerber J.G., Bassett R., Morse G.D., DiFrancesco R, Hammer S.M. for ACTG 372A team. Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V for the ACTG 372B/D Study Team. A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1 Infected Persons with Virologic Failure Receiving Indinavir. Antivir Ther. 2003;8 (6):507-18. Laboratory Analyses: By LCMSMS –Indinavir trough and peak concentrations ACTG 368 - Phase I/II Randomized, Double Blind, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneous Bay 50-4798 (IL-2 Selective Agonist [IL-2 SA]) administration in patients with HIV infection on HAART compared to Patient DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD and the Adult AIDS Clinical Trials Group Protocol 368/886 Study Team. Indinavir, Efavirenz and Abacavir Pharmacokinetics in HIV-Infected Subjects. Antimicrob Agent Chemother 2003; 47; 1929-1935.
Laboratory Analyses: by HPLC indinavir, efavirenz PK Analyses ACTG 260 - Randomized, Phase I/II Dose Ranging, Open Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (U-90,152S) Smith PF, DiCenzo R, Forrest A, DiFrancesco R, Para M, Friedland G, Fischl M, Pollard R, Morse GD and the ACTG 260 and 261 Protocol Teams. Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV Infection Clin Pharmacokin 2005;44(1):99-109. Para Mf, Meehan P, Holden-Wiltse J, Fischl M, Morse G, Shafer R, Demeter LM, Wood K, Nevin T, Virani-Ketter N, Freimuth WW. A randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The ACTG 260 Team. Antimicrob Agent Chemother 1999; 43:1373-1378. Laboratory Analyses: delavirdine and N—delavirdine, REAL-TIME reporting PK Analyses ACTG 261 – A Phase II Double-Blind Study Of Delavirdine Mesylate (DLV) In Combination With Zidovudine (ZDV) And/Or Didanosine (DDI) Versus ZDV And DDI Combination Therapy PF Smith, R DiCenzo, A Forrest, MJ Shelton, G Friedland, M Para, R Pollard, M Fischl, R DiFrancesco, GD Morse. Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals. Clinical Pharmacokinetics 2005;44 ;99 -109 Laboratory Analyses: delavirdine and N—delavirdine, REAL-TIME reporting PK Analyses ACTG 388 - A Phase III, Randomized, Controlled Trial of Efavirenz (EFV) or Nelfinavir (NFV) in Combination with Fixed-Dose Combination Lamivudine/Zidovudine (3TC/ZDV) and Indinavir (IDV) in HIV-Infected Subjects with <=200 CD4 Cells/MM3 or >= 80,000 HIV RNA Copies/mL Friedland GH, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M, Fischl M, for the ACTG 261 Team. The efficacy and safety of delavirdine mesylate in combination with zidovudine and didanosine in the treatment of HIV disease (ACTG 261). JAIDS 1999;21:281-292. DiCenzo R, Forrest A, Fischl, MA, Collier A, Feinberg J, Ribaudo H, DiFrancecso R, Morse GD, Pharm.D and the ACTG 388/733/5060 Study Team. Pharmacokinetics of Indinavir and Nelfinavir in Treatment-Naïve, HIV-Infected Subjects. Antimicrobial Agent Chemother 2004 48(3), 918-923. PK Analyses OTHER ACTG PUBLICATIONS Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Jr, Donahue JP, Kim RB Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 1;192(11):1931-42. Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics. 2006 Nov;16(11):837-45. Fischl MA, Ribaudo HJ, Collier AC, Erice A, Marina G, Dehlinger M, Eron JJ, Saag MS, Hammer SM, Vella S, Morse GD Feinberg JE for the AIDS Clinical Trials Group 388 Study Team. A Randomized Trial Comparing Two Different Four-Drug Antiretroviral Regimens with a Three-Drug Regimen in Persons with Advanced HIV Disease. J. Infect Dis. 2003;188 (5):625-34. Pharmacology and Laboratory Technology Protocol Contributions Gene D. Morse January 2004-present Investigator, ACTG 5213 Mar 2006 –present Protocol Pharmacologist, ACTG Protocol 5236 Jul 2001 –Jan 2003 Protocol Pharmacologist, ACTG Protocol 5149 Jul 2001 -present Protocol Pharmacologist, ACTG Protocol 5146 Jul 2001 – Jan 2003 Protocol Pharmacologist, ACTG Protocol 5135 Jan 2000 – Dec 2001 Chair, Adult ACTG Pharmacology Committee Mar 1999 - present Protocol Chair, ACTG Protocol 5043 Nov 1997 –Jan 2006 Protocol Pharmacologist, ACTG Protocol 388 Oct 1997 -present Protocol Pharmacologist, ACTG Protocol 384 Mar 1997 –Jan 2006 Protocol Pharmacologist, ACTG Protocol 372 Mar 1997 –Dec 1999 Vice Chair, ACTG Adult Pharmacology Committee Mar 1997 –Jan 2002 Protocol Pharmacologist, ACTG Protocol 368 Mar 1997 –Jan 2002 Protocol Pharmacologist, ACTG Protocol 868 Mar 1997 –Jan 2002 Protocol Pharmacologist, ACTG Protocol 370 Jan 1997 –Dec 2004 Member, ACTG HIV Research Agenda Committee Sept 1993 - Jan 1999 Protocol Pharmacologist, ACTG Protocol 260 June 1993 - Jan 1999 Protocol Pharmacologist, ACTG Protocol 261 Nov 1991 - Jan 1999 Protocol Pharmacologist, ACTG Protocol 187 Nov 1991 - Jan 1999 Protocol Pharmacologist, ACTG Protocol 199 Sept 1991 - Dec 1992 Protocol Pharmacologist, ACTG Protocol 143 Mar 1988 - Mar 1992 Member, ACTG, NIAID, Pharmacology Committee Oct 1991 - Mar 1992 Member, ACTG, NIAID, Opportunistic Infectious Committee Sept 1991- Mar 1992 Protocol Pharmacologist, ACTG Protocol 135 Jan 1991 - Mar 1992 Protocol Pharmacologist, ACTG Protocol 156 Robert DiCenzo Jul 2001 -present Protocol Pharmacologist, ACTG Protocol 5146 Kelly Tooley Laboratory Technologist, ACTG 5164 Laboratory Technologist, ACTG 5168s Laboratory Technologist, ACTG5177 Laboratory Technologist, ACTG 5188 Laboratory Technologist, ACTG 5223 Laboratory Technologist, ACTG 5236 Robin DiFrancesco Laboratory Technologist, ACTG 5043 Laboratory Technologist, ACTG 5108 Laboratory Technologist, ACTG 5126 Laboratory Technologist, ACTG 5135 Laboratory Technologist, ACTG 5146 Laboratory Technologist, ACTG 5191 Laboratory Technologist, ACTG 5200 Laboratory Technologist, ACTG 5208 Laboratory Technologist, ACTG 5213 Laboratory Technologist, ACTG 5217 Laboratory Technologist, ACTG 5230 Laboratory Technologist, IMPAACT 1021 Laboratory Technologist, IMPAACT 1058
Pharmacology Quality Assurance (PQA) program Mission of PQA The goal of the ACTG Pharmacology Quality Assurance (QA) Program is to provide mechanisms that assure, in a timely manner, the validity and integrity of the data produced in pharmacology-related AIDS Clinical Trials Group (ACTG) research trials. In 2000, a new Quality Assurance Program for ACTG Pharmacology Studies was strategized by Dr. Gene Morse and began implementation. By identifying the common problems and errors occurring within prior clinical trial studies and utilizing the quality procedures inherent within Good Clinical Practice Regulations (GCP), Good Laboratory Practice (GLP) Regulations and the Clinical Laboratory Improvement Act (CLIA), specific program components were designed. The latter regulation, CLIA, is required for ACTG Pharmacology Support Laboratories (PSL) generating laboratory results directly impacting patient care. New pharmacology quality assurance practices were implemented throughout the conduct of ACTG clinical trials. Program Components There are six main components to the program: [1] GCRC certification (PK tutorial program which certifies sites for PK studies) [6] Development, Implementation and Maintenance of Quality Assessments for specimens (LDMS reports such as patient sample projections, dose interval reports, inventories, TDM report modules, etc) PQA Publications: D. Holland, R. DiFrancesco, Judith Stone, F. Hamzeh, James D. Connor and GD Morse Quality Assurance Program for Clinical Measurement of Antiretrovirals: AACTG Proficiency Testing Program for Pharmacology Laboratories. Antimicrobial Agent Chemother 2004 48(3), 824-831. Robin DiFrancesco, Diane T. Holland, Joanne E. Schiffhauer, Brian L. Robbins, Kelly M. Tooley, and Gene D. Morse. A Quality Assurance Program for AIDS Clinical Trials Group Pharmacology Studies. Journal of Quality Assurance March 2005. DT Holland, R DiFrancesco, JD Connor , GD Morse. ACTG Proficiency Testing for Pediatric and Adult Pharmacology Support Laboratories. Ther Drug Monitoring 2006 Jun;28(3):367-74. DiFrancesco R, Rosenkranz SL, Craft J, Morse GD. Abstract Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpoints. HIV Clin Trials. 2006 Jul-Aug;7(4):203-9 Committee Participation Gene D. Morse Sept 2006-present Member, R5 Tropic Protocol Committee Jan 2005-present Member, ACTG Experimental Research Agenda Committee May 2004-present Chair, ACTG Pharmacology Lab Subcommittee June 2003-April 2004 Vice-Chair, ACTG Pharmacology Lab Subcommittee January 2002-present Member, ACTG Pharmacology Leadership Subcommittee Jan 2000-present Chair, ACTG Pharmacology QA-QC Subcommittee Jan 2000 – present Chair, Pharmacology Quality Assurance (ACTG and IMPAACT) Robert DiCenzo Member Pharmacology Committee Drug Interactions Table Editor Robin DiFrancesco Member Laboratory Technologists Committee (ACTG and IMPAACT) Member Pharmacology Quality Assurance (ACTG and IMPAACT) Kelly Tooley Member Laboratory Technologists Committee (ACTG and IMPAACT)
|
